Doron Therapeutics, a clinical-stage biotechnology company based in Chapel Hill, has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients.

BRUSSELS (Reuters) - The EU Commission on Wednesday said it had unconditionally approved the $2.3 billion acquisition of U.S. optical semiconductors and networking equipment maker Infinera (INFN) by ...

BRUSSELS (Reuters) - The EU Commission on Wednesday said it had unconditionally approved the $2.3 billion acquisition of U.S. optical semiconductors and networking equipment maker Infinera (INFN ...

The new drug application has also been officially accepted in mainland China and Hong Kong, and etrasimod has officially been approved for adult patients with moderately to severely active UC by the ...

MELBOURNE, Australia and INDIANAPOLIS, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment; Etrasimod demonstrates robust efficacy across multiple endpoin ...

Tata Sons is its top shareholder, with a 92.8% stake as of March 2024. The company separately also approved a 15.04 billion rupees ($173 million) rights issue on Tuesday.

SAO PAULO, Feb 25 (Reuters) - Support for Brazil's President Luiz Inacio Lula da Silva has dipped sharply and now trail his disapproval rating, a CNT/MDA poll showed on Tuesday, the latest in a ...

President Trump holds a 52 percent approval rating in after his first month back in the Oval Office, polling shows. A Harvard CAPS/Harris survey found that 33 percent strongly approved of the ...

BridgeBio Pharma has received European approval for a drug that treats cardiomyopathy stemming from a rare metabolic condition, strengthening the biotech’s position to take market share from the ...